XXXX for the treatment of behavioural alterations in @entity303 : preliminary 15-month investigation.

@entity1 @entity1538 @entity2682 @entity13675 @entity303 @entity73 @entity1067 @entity8442 @entity1578 @entity1245 @entity195
BACKGROUND: Although the core feature of @entity303 is progressive @entity73 , non-cognitive behavioural problems are expressed in most @entity1 with @entity303 during the course of their illness. While psychotropic drugs are frequently used to control behavioural symptoms, comorbidities, which are very common in the geriatric population, could often limit their use. @entity2682 may be a potential treatment in such situations. METHODS: In this open, baseline comparison study 20 @entity1 with probable @entity195 with behavioural alterations and serious comorbidities ( @entity8442 , @entity1538 , @entity13675 , @entity1578 or severe @entity1067 ) received @entity2682 for 15 months. @entity1 were allowed to continue any previous therapy for concurrent diseases. However, concomitant antipsychotic or @entity1245 intake was not permitted. RESULTS: @entity2682 appeared to be efficacious and well tolerated in this @entity1 population, and did not appear to interact with other drugs. General benefit is reflected by a reduction of caregiver stress. No @entity1 withdrew before the end of the study and no serious adverse events were reported. CONCLUSION: The results of this study in @entity1 with probable @entity195 with behavioural alterations and serious comorbidities indicate that @entity2682 provides significant and sustained efficacy in terms of behaviour, with associated reductions in caregiver burden. The results of an ongoing larger, randomised, double-blind study of @entity2682 are keenly awaited and may help to provide a safer and more efficacious treatment option for this group of @entity1 .
